The AbbVie Migraine Career Catalyst Award™ contest is now open for entries, offering financial support to help winners pursue career and professional development goals. As the only company with ...

“Our work unlocks a scalable, off-the-shelf solution for ocular surface reconstruction,” said Dr. Jessica M. Gluck, senior author of the study. “DDHAM-3L demonstrates its biocompatibility ...

The eye’s remarkable complexity makes it vulnerable to a wide spectrum of conditions, from localized issues affecting only ocular structures ... often described as a curtain, shadow, or veil ...

Migraine with aura is the most prominent individual risk factor for unexplained stroke in adults younger than 50 years, particularly in women and in those with patent foramen ovale (PFO), a new ...

Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment ...

Credit: Axsome Therapeutics Symbravo is expected to be available in approximately 4 months. Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug ...

Experiencing flashing lights in your eyes could be a sign of a variety of issues. Such flashes, also known as photopsia, can be a symptom of different conditions, including a retinal detachment, where ...

Please provide your email address to receive an email when new articles are posted on . E-cigarette users had significant average meibomian gland loss on both lids compared with non-users.

Migraine is a major source of absenteeism or being present at work but not being able to give your full effort. Migraine costs American companies billions of dollars annually in lost work ...